Role of CHF1 in Occlusive Vascular Disease

CHF1 在闭塞性血管疾病中的作用

• 批准号: 7099617
• 负责人: MICHAEL T CHIN
• 金额: --
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-01 至 2006-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7099617
• 关键词: angiogenesis; apolipoprotein E; apoptosis; atherosclerosis; biological signal transduction; disease /disorder model; epidermal growth factor; genetic susceptibility; genetically modified animals; guanine nucleotide binding protein; heparin; laboratory mouse; pathologic process; platelet derived growth factor; protein tyrosine kinase; transcription factor; vascular endothelium; vascular smooth muscle

DESCRIPTION (provided by applicant): The transition of vascular smooth muscle cells from a differentiated, contractile to a proliferative, migratory and synthetic phenotype is hypothesized to be important in the development of occlusive vascular lesions. The genetic switches that regulate this phenotypic transition are not completely understood. We have previously identified CHF1, a bHLH transcription factor expressed in the cardiovascular system, as an important regulator of ventricular septation and function. We hypothesize that this protein is also a critical regulator of vascular smooth muscle cell (VSMC) function in the development of vascular disease. Our preliminary data from CHF1 knockout mice support this hypothesis, in that these mice show decreased neointimal formation after vascular injury, and that VSMCs from these mice show decreased migration in response to platelet derived growth factor (PDGF) and heparin binding epidermal growth factor (HB-EGF). The molecular defect at least partially involves attenuation of Racl activation. Our specific aims are: Aim 1: Characterize the molecular phenotype of VSMCs lacking CHF1 and determine the basis for decreased responsiveness to growth factors We will measure expression and activation of known components of the PDGF and HB-EGF signaling pathways, focusing initially on regulators of Racl activity. We will also perform a genomic analysis of wild type and knockout cells at varying time points after PDGF stimulation. Aim 2: Generate conditional CHF1 KO mice lacking CHF1 specifically in vascular smooth muscle. At present, it is unclear whether decreased neointima after injury in CHF1 KO mice is due to effects on local vascular smooth muscle, endothelium, circulating stem cells, or through a combination of cell types. To address this question, we will generate conditional knockout mice that lack CHF1 specifically in the smooth muscle layer of the vessel wall and then assess their response to vascular injury. Aim 3: Measure the effect of vascular smooth muscle cell CHF1 deficiency on experimental atherosclerosis. We hypothesize that CHFl-mediated effects on vascular smooth muscle are essential for the development of atherosclerotic lesions. We will cross conditional knockout mice lacking CHF1 in vascular smooth muscle with ApoE null mice and measure the development of atherosclerotic lesions in the double knockout mice.

描述(由申请人提供)：血管平滑肌细胞从分化的、收缩的向增殖、迁移和合成的表型转变被认为在闭塞血管病变的发展中是重要的。调节这种表型转变的遗传开关还没有完全被理解。CHF1是一种在心血管系统中表达的bHLH转录因子，是室间隔和功能的重要调节因子。我们推测，该蛋白也是血管平滑肌细胞(VSMC)在血管疾病发展过程中功能的关键调节因子。我们来自CHF1基因敲除小鼠的初步数据支持这一假说，因为这些小鼠血管损伤后新生内膜形成减少，这些小鼠的VSMCs对血小板衍生生长因子(PDGF)和肝素结合表皮生长因子(HB-EGF)的反应迁移减少。分子缺陷至少部分涉及Rac1活性的减弱。我们的具体目标是：目标1：确定缺乏CHF1的VSMC的分子表型，并确定对生长因子反应性降低的基础。我们将测量PDGF和HB-EGF信号通路的已知成分的表达和激活，最初关注的是racl活性的调节。我们还将对PDGF刺激后不同时间点的野生型和基因敲除细胞进行基因组分析。目的2：建立血管平滑肌特异性CHF1缺失的条件性CHF1 KO小鼠。目前，尚不清楚CHF1 KO小鼠损伤后新生内膜减少是由于局部血管平滑肌、内皮、循环干细胞的影响，还是通过多种细胞类型的组合。为了解决这个问题，我们将产生在血管壁的平滑肌层中缺乏CHF1的条件性基因敲除小鼠，然后评估它们对血管损伤的反应。目的3：检测血管平滑肌细胞CHF1缺陷对实验性动脉粥样硬化的影响。我们假设CHF1介导的血管平滑肌效应在动脉粥样硬化病变的发展过程中是必不可少的。我们将血管平滑肌中缺乏CHF1的条件性基因敲除小鼠与ApoE基因缺失的小鼠交叉，并测量双基因敲除小鼠动脉粥样硬化病变的发展情况。